Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of “Moderate Buy” by Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average rating of “Moderate Buy” from the twenty-four ratings firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $396.7167.

Several equities analysts recently weighed in on ALNY shares. Wells Fargo & Company cut their target price on shares of Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. Chardan Capital reiterated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. cut their price objective on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $219.20 on Monday. Alnylam Pharmaceuticals has a 1 year low of $197.81 and a 1 year high of $495.55. The firm’s 50 day moving average price is $280.12 and its 200-day moving average price is $305.89. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a market cap of $29.33 billion, a P/E ratio of 40.74 and a beta of 0.30.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $455 price target. Although the firm lowered its 2026, 2028, 2029 and 2030 EPS forecasts, it raised its FY2027 estimate to $9.50 from $8.13, signaling expectations for continued longer-term earnings growth. HC Wainwright estimates for Alnylam Pharmaceuticals
• Neutral Sentiment: Several HC Wainwright revisions reduced projected EPS, including Q3 2026 to $1.65 from $1.79, Q4 2026 to $1.97 from $2.23, and FY2026 to $6.30 from $6.51. The firm’s estimates remain broadly positive beyond 2026, reaching $19.42 per share by FY2030, but the near-term reductions could limit enthusiasm. Alnylam Pharmaceuticals earnings estimates
• Neutral Sentiment: An AAII comparison examines whether Alnylam or Halozyme Therapeutics is the more attractive investment. The article may influence investor preferences, but it does not identify a new company-specific operating catalyst. Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. Stock?
• Neutral Sentiment: Options-market implied volatility for ALNY has surged, pointing to increased expectations for price movement and trading risk rather than a clear bullish or bearish fundamental signal. Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
• Negative Sentiment: Truist Financial lowered its price target on Alnylam to $315, a more cautious valuation view that could weigh on the stock and reflects concern about the company’s risk-reward profile. Truist Financial Lowers Alnylam Pharmaceuticals Price Target

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. First Horizon Corp lifted its stake in Alnylam Pharmaceuticals by 20.7% in the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 28 shares during the period. Yousif Capital Management LLC increased its position in Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock valued at $666,000 after purchasing an additional 29 shares during the period. Daiwa Securities Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.